Intact Investment Management Inc. Makes New $650,000 Investment in DexCom, Inc. (NASDAQ:DXCM)

Intact Investment Management Inc. purchased a new position in DexCom, Inc. (NASDAQ:DXCM - Free Report) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 9,700 shares of the medical device company's stock, valued at approximately $650,000.

A number of other institutional investors and hedge funds also recently modified their holdings of DXCM. Migdal Insurance & Financial Holdings Ltd. purchased a new position in DexCom in the second quarter valued at approximately $25,000. Sachetta LLC boosted its holdings in DexCom by 255.2% in the second quarter. Sachetta LLC now owns 238 shares of the medical device company's stock valued at $27,000 after purchasing an additional 171 shares during the last quarter. Crewe Advisors LLC acquired a new position in shares of DexCom in the 1st quarter valued at approximately $29,000. Riverview Trust Co boosted its stake in shares of DexCom by 100.4% during the 3rd quarter. Riverview Trust Co now owns 463 shares of the medical device company's stock valued at $31,000 after buying an additional 232 shares during the last quarter. Finally, DT Investment Partners LLC grew its position in shares of DexCom by 492.2% during the second quarter. DT Investment Partners LLC now owns 379 shares of the medical device company's stock worth $43,000 after buying an additional 315 shares in the last quarter. Institutional investors and hedge funds own 97.75% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on DXCM. Royal Bank of Canada decreased their price objective on shares of DexCom from $120.00 to $115.00 and set an "outperform" rating for the company in a report on Friday, October 25th. Oppenheimer cut their price objective on DexCom from $115.00 to $105.00 and set an "outperform" rating on the stock in a research note on Friday, October 25th. Morgan Stanley decreased their target price on DexCom from $120.00 to $75.00 and set an "equal weight" rating for the company in a research report on Friday, July 26th. Baird R W lowered DexCom from a "strong-buy" rating to a "hold" rating in a research report on Friday, July 26th. Finally, Robert W. Baird increased their target price on shares of DexCom from $80.00 to $82.00 and gave the stock a "neutral" rating in a report on Monday, August 5th. Seven research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, DexCom presently has an average rating of "Moderate Buy" and a consensus target price of $104.59.

DexCom Price Performance

NASDAQ:DXCM traded down $0.70 during mid-day trading on Tuesday, reaching $69.00. 3,405,130 shares of the stock were exchanged, compared to its average volume of 3,901,250. DexCom, Inc. has a 1-year low of $62.34 and a 1-year high of $142.00. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23. The firm has a market capitalization of $26.95 billion, a PE ratio of 41.32, a PEG ratio of 2.16 and a beta of 1.17. The business has a fifty day moving average price of $69.77 and a 200 day moving average price of $94.92.

Insider Transactions at DexCom

In related news, COO Jacob Steven Leach sold 746 shares of the stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $51,585.90. Following the completion of the transaction, the chief operating officer now owns 264,915 shares in the company, valued at $18,318,872.25. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other DexCom news, EVP Sadie Stern sold 426 shares of the business's stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $29,457.90. Following the sale, the executive vice president now directly owns 75,451 shares of the company's stock, valued at $5,217,436.65. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Jacob Steven Leach sold 746 shares of the stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $51,585.90. Following the completion of the sale, the chief operating officer now owns 264,915 shares of the company's stock, valued at $18,318,872.25. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.30% of the company's stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.